🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

First Newborn Recruited for New Sepsis Study Neonatal sepsis affects up to three million babies a year globally. ✍️@KerryCullinan11 Global Antibiotic R&D Partnership (GARDP) Drugs for Neglected Diseases initiative School of Health & Medical Sciences MRC Clinical Trials Unit at UCL healthpolicy-watch.news/first-newborn-…

Proud to join the ComBac-Africa consortium—a new EU-funded effort to tackle drug-resistant infections in Africa. Led by Saarland University with partners including GARDP, it will strengthen diagnostics & access to antibiotics in sub-Saharan Africa where the highest #AMR

Grateful to C-CAMP for convening the India AMR Innovation Workshop. We shared how contextual innovation paired with global access frameworks can strengthen India’s leadership in the #AMR response. Thanks to all partners advancing science-based solutions where they’re

🚩 A major milestone for global antibiotic access! GARDP signs an agreement with Dr. Reddy’s Laboratories Ltd to market zoliflodacin—an investigational first-in-class oral antibiotic for #gonorrhoea in 🇹🇭 Thailand and 🇿🇦 South Africa, where GARDP-led Phase 3 trials showed promising results. 🔗

We need to improve the global #AMR response for children and newborns!👶 At GARDP, we’re working to develop new treatments for children, especially newborns with sepsis. 📢 Join the #ThisIsBig campaign to ensure children are no longer left behind. 🔗gardp.org/neonatal-sepsi…

Thank you Bangkok 🇹🇭 Our Global Access Director, Jennifer Cohn, participated in a meeting on "Improving priority antibiotic access in Thailand and regional procurement mechanisms". Organized by HITAP with World Health Organization (WHO) and Global Antibiotic R&D Partnership (GARDP), the meeting brought together

💊Repurposing drugs is a promising option to find new treatments for antimicrobial resistance, especially at a time when the pipeline for new antibiotics is running dangerously dry. 🗓️Join us on 22 July to hear how researchers are finding new antibiotic potential in existing

🤝GARDP has teamed up with AI experts at Ersilia and at the H3D to seek an innovative solution to antimicrobial resistance. We are building AI models to identify new molecules with activity against deadly bacterial pathogens such as Klebsiella pneumoniae. This pathogen has

🚨GARDP and Bugworks partner to co-develop oral formulation of BWC0977 — a promising broad-spectrum antibiotic. This oral version is a critical advancement, offering: 🔹 A much-needed 𝐬𝐭𝐞𝐩-𝐝𝐨𝐰𝐧 𝐨𝐩𝐭𝐢𝐨𝐧 𝐟𝐫𝐨𝐦 𝐢𝐧𝐭𝐫𝐚𝐯𝐞𝐧𝐨𝐮𝐬 (𝐈𝐕) 𝐭𝐡𝐞𝐫𝐚𝐩𝐲,

🚨 新たな日本でのパートナーシップ！ GARDP 🤝 Science Tokyo （東京科学大学） #薬剤耐性 菌に対する新たな抗菌薬の開発に向け、東京科学大学の村上聡教授とタンパク質と化合物の結合構造の解明に取り組みます🧬💊 🔗プレスリリースはこちら: x.gd/RhpRg #AMR #グローバルヘルス

🚨 New Partnership Alert! GARDP 🤝 Science Tokyo (Institute of Science Tokyo) We’re teaming up with Prof. Satoshi Murakami to unlock protein-compound structures that could lead to new antibiotics for drug-resistant infections. 🧬💊 Read the full PR here: gardp.org/gardp-and-inst… #AMR #DrugDiscovery

💥New development in a novel broad-spectrum antibiotic from India! #Bugworks, a CCAMP supported and incubated startup, has partnered with Global Antibiotic R&D Partnership (GARDP) to co-develop the oral formulation of their novel broad spectrum anti-bacterial candidate - BWC0977! Already in clinical trials

From Australia to the UK to Switzerland, researchers are rethinking what old medicines can do. Join REVIVE’s webinar on 22 July (tomorrow), where leading scientists will discuss repurposing drugs meant for other diseases as effective antibiotics. 🗓️ 09:30-11:00 CEST 🔗 Register

🩹💊 When lives are on the line, clinicians often reach for antibiotic combinations based on in vitro promise. But do they help or harm? In our new #REVIVE Viewpoint, Dr Angela Huttner @HUG calls for robust clinical data to back decisions that are too important to just make a

A new The Guardian article highlights the alarming economic impact of AMR if we continue business as usual. The report findings are — 💸 $2 trillion in global economic losses annually by 2050 📷 Millions of lives at risk from drug-resistant infections Cuts to AMR programmes,

🌟GARDP has completed its study on the prevalence of gonorrhoea and chlamydia in Lusaka, 🇿🇲Zambia, to get a better understanding of the burden of these STIs. 👏 Many thanks to CIDRZ NGO & excellent site team 👩‍⚕️

One Health AMR Challenge 2025 of C-CAMP, supported by Int. Centre for Antimicrobial Resistance Solutions, is now open for startups, companies & institutions bringing forward AMR solutions. If you're working on game-changing tools or ideas in the AMR space, this is your moment. Open to 🇮🇳 and eligible global

📰 The Nikkan Kogyo Shimbun covers GARDP’s new joint research with Science Tokyo (Institute of Science Tokyo) on developing novel antibiotics to address drug-resistant infections. Read the story here : nikkan.co.jp/articles/view/…